LOTUS2: Наблюдательное исследование эффективности и безопасности терапии инсулином гларгин (лантус) в повседневной клинической практике у пациентов с сахарным диабетом 2-го типа, не достигших целевого гликемического контроля на терапии инсулином детемир
https://doi.org/10.14341/probl201359525-31
Аннотация
Список литературы
1. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., Zinman B. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17-30.
2. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44: 11: 1249-1258.
3. Holman R.R., Farmer A.J., Davies M.J., Levy J.C., Darbyshire J.L., Keenan J.F., Paul S.K. 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736-1747.
4. Riddle M.C., Umpierrez G., Digenio A., Zhou R., Rosenstock J. Challenging the "Monnier Concept": High Basal (not Postprandial) Glucose Dominates Hyperglycemic Exposure over a Wide Range of A1C on Oral Therapy, and Contributes Significantly Even after Addition of Basal Insulin. Diabetes 2010; 59: Suppl 1: Abstract: 626.
5. Freemantle N., Balkau B., Danchin N., Admane K., Marre M., Home Ph., Blonde L. Cardiovascular (CV) Risk Evaluation in People with Type 2 Diabetes (T2D) on Insulin Therapy (CREDIT) Study - CV Disease and CV Risk at Baseline. Diabetes 2009; 58: Suppl 1: Abstract: 474.
6. DeVries J.H., Meneghini L.F., Barnett A.H., Reid T., Dain M.P., Landgraf W., Vlajnic A., Traylor L., Bergenstal R.M. Pooled Hypoglycemia Event Rates With Insulin Glargine Added to Metformin from Treat-To-Target Type 2 Diabetes Mellitus (T2DM) Trials. Diabetes 2012; 61: Suppl 1: А 552-553: Abstract: 2172-PO.
7. Home P.D., Fritsche A., Schinzel S., Massi-Benedetti M. Metaanalysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metabol 2010; 12: 772-779.
8. Mullins P., Sharplin P., Yki-Jarvinen H., Riddle M.C., Haring H.U. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007; 29: 1607-1619.
9. Swinnen S.G., Simon A.C., Holleman F., Hoekstra J.B., Devries J.H. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011; 7: CD006383.
10. Meneghini L., Kesavadev J., Demissie M., Nazeri A., Hollander P. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Diabetes Obes Metabol 2013; 15: 8: 729-736.
11. Ligthelm R.J., Borzi V., Gumprecht J., Kawamori R., Wenying Y., Valensi P. Importance of observational studies in clinical practice. Clin Ther 2007; 29: 1284-1292 (Special Nomer).
12. Dixon S., Peters J.R. Evaluating the 'real' costeffectiveness of health technology: reconciling the public interest with patients' interests. Curr Med Res Opin 2007; 23: Suppl 1: S1-S6.
13. Hajos T.R., Pouwer F., de Grooth R., Holleman F., Twisk J.W., Diamant M., Snoek F.J. The longitudinal association between glycaemic control and health-related quality of life following insulin therapy optimisation in type 2 diabetes patients. A prospective observational study in secondary care. Qual Life Res 2012; 21: 8: 1359-1365.
14. Meneghini L., Koenen C., Weng W., Selam J.L. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes-results of the randomized, controlled PREDICTIVE 303 study. Diabet Obes Metabol 2007; 9: 902-913.
15. Lieverse L. et al. Improved glycaemic control with once-daily insulin glargine in people with type 2 diabetes inadequately controlled on insulin detemir/OAD combination therapy (RESOLUTE). Diabetologia 2012; 55: Suppl. 1: Abstract 947.
16. Veneman T.F., Storms F.E.M.G., Eland I.A., Bouter P.K.P. From insulin detemir to glargine: Effect on glycemic control and psychological wellbeing in patients with diabetes mellitus type 2 in daily practice. J Diabetes Mellitus 2012; 2: 101-108.
Рецензия
Для цитирования:
LOTUS2: Наблюдательное исследование эффективности и безопасности терапии инсулином гларгин (лантус) в повседневной клинической практике у пациентов с сахарным диабетом 2-го типа, не достигших целевого гликемического контроля на терапии инсулином детемир. Проблемы Эндокринологии. 2013;59(5):25-31. https://doi.org/10.14341/probl201359525-31
For citation:
Glinkina I.V. LOTUS2: The observational study of the effectiveness and safety of insulin glargine (lantus) in the routine clinical practice for the patients with type 2 diabetes mellitus failing to achieve the targeted glycemic control using insulin detemir. Problems of Endocrinology. 2013;59(5):25-31. (In Russ.) https://doi.org/10.14341/probl201359525-31
Контент доступен под лицензией Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).